MYND Gives Back Gains, RSLS Hits New Low, IDRA Has Its Work Cut Out

(RTTNews) - The following are some of the healthcare stocks that posted the biggest percentage decline today.

1. MYnd Analytics Inc. (MYND)

MYnd is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients.

Lost 22.04% to close Tuesday's (Jul 31) trading at $1.45. The stock has given back most of what it gained yesterday.

News: No news

Recent event:

On July 30, the Company announced that it has launched a new program offering behavioral health solutions for skilled nursing and assisted living facilities, which will be deployed at the Bayside Health and Rehabilitation skilled nursing facility in Florida. The news sent the stock soaring 33.81% to $1.86 yesterday.

2. ReShape Lifesciences Inc. (RSLS)

ReShape is a medical device company focused on technologies to treat obesity and metabolic diseases. It has two FDA-approved products, ReShape Intragastric Balloon and ReShape vBloc therapy.

Lost 12.50% to close Tuesday's trading at $1.05. The stock touched a new low of $1.04 in intraday trading.

News: No news

Recent events:

On July 11, the Company announced that it entered into definitive agreements with several institutional investors for the purchase of 1.24 million shares of its common stock, at a purchase price per share of $2.05, for gross proceeds of roughly $2.55 million, in a registered direct offering priced at-the-market.

Near-term Catalyst:

-- Enrollment in a multi-center trial of ReShape Vest to support CE Mark approval is expected to begin in the third quarter of 2018.

The ReShape Vest is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

3. Idera Pharmaceuticals Inc. (IDRA)

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases.

Lost 12.82% to close Tuesday's trading at $5.71.

News: No news

Recent events:

On July 30, a one-for-eight reverse stock split of common stock was implemented.

Near-term Catalysts:

-- Complete enrollment of a phase I/II trial of Tilsotolimod in combination with Ipilimumab in patients with PD-1 refractory melanoma, dubbed ILLUMINATE-204, by year end 2018.

ILLUMINATE-204 is a phase I/II trial of Tilsotolimod in combination with Ipilimumab or Pembrolizumab in patients with PD-1 refractory melanoma.

-- Data update following completion of ILLUMINATE-204 Pembrolizumab combination Phase 1 component of the trial. -- Data from a phase I study of Tilsotolimod in patients with refractory solid tumors, dubbed ILLUMINATE-101. -- Complete enrollment in ILLUMINATE-204 with top line data in mid-2019.

4. RedHill Biopharma Ltd. (RDHL)

RedHill is a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases.

Lost 11.20% to close Tuesday's trading at $7.77.

News: No news

Recent Events:

On July 30, the Company announced positive top-line safety and efficacy results from the first Phase III study with RHB-104 for Crohn's disease (the MAP US study). The study successfully met its primary endpoint and key secondary endpoints.

An open-label extension Phase III study (MAP US2 study) is ongoing to evaluate the safety and efficacy of RHB-104 in subjects who remain with active Crohn's disease after 26 weeks of blinded study therapy in the Phase III MAP US study.

On July 20, the American Depositary Shares of RedHill were uplisted to Nasdaq Global Market from the Nasdaq Capital Market.

Near-term Catalysts:

-- Complete enrollment in a confirmatory Phase III study investigating TALICIA for H. pylori infection, dubbed ERADICATE Hp2, in the coming weeks. -- Announce top-line results from ERADICATE Hp2 study in Q4, 2018. -- Initiation of a pivotal Phase III study of RHB-204 for the treatment of nontuberculous mycobacteria (NTM) infections in the second half of 2018.

5. Adamis Pharmaceuticals Corporation (ADMP)

Adamis is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.

Lost 11.11% to close Tuesday's trading at $3.20.

News: No news

Products & Pipeline:

The Company's Symjepi (epinephrine) Injection 0.3mg was approved by the FDA last June for the emergency treatment of allergic reactions (Type I) including anaphylaxis.

Symjepi (epinephrine) Injection 0.15mg product is under FDA review, with a decision expected on September 3, 2018.

Also in the pipeline are APC-6000- Naloxone Injection for opioid overdose, APC-1000- HFA Inhaled Oral Steroid and APC-4000- Fluticasone DPI for asthma/COPD.